CAL02 - First-in-class life-saving drug

Results in severe pneumonia patients ranked “a medical breakthrough”.
The Lancet Infectious Diseases 
(Laterre et al. 2019; Pletz et al. 2019)

 Designed to fight severe bacterial and viral infections.

Developped by LASCCO’s spin-off Combioxin SA


Restoring health in critically ill patients suffering of severe infections

The unique therapeutic approach of CAL02 consists in using liposomes engineered to neutralize virulence effectors playing a critical role in the development of organ failure and fatal complications in severe infections.

CAL02 is a phase 2-stage drug that has successfully been tested in ICU patients with severe community-acquired pneumonia.

Combioxin’s Latest news

Combioxin receives positive feedback from FDA on its pre-investigational new drug (PIND) application for use of CAL02 in COVID-19 patients at risk of severe bacterial infections.
May 4, 2020

Selected publications